Compare Heron Therapeutics Inc (HRTX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Tripadvisor Inc Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Tripadvisor Inc Common Stock trades at $13.89 (market cap $1.68B). The key difference: Tripadvisor Inc Common Stock is far larger — about 18.4× Heron Therapeutics Inc's market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | TRIP | |
|---|---|---|
Market Cap | $91.46M | $1.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $19.14 |
52-Week Low | $0.39 | $9.24 |
Enterprise Value | $189.36M | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Tripadvisor (TRIP) trades at $14.38, down 1.37% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q1 2026 earnings miss but maintains strong gross margins of 91.95%. Recent $700 million sale of TheFork to American Express provides capital flexibility while focusing on core travel experiences business. Revenue growth remains modest at $1.89B in 2025 with net margin improving to 2.11%.
Outlook remains cautious with analyst consensus at Hold (60.72%) and $13.87 price target below current levels. The stock faces headwinds from competitive pressures and macroeconomic uncertainty, though the strategic divestiture and travel recovery trends offer potential upside. Key risks include execution challenges and market volatility amid mixed earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
